- Home
- UVSP vs GLUE Comparison
UVSP vs GLUE Comparison
Compare UVSP & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UVSP | GLUE |
|---|---|---|
| Founded | 1876 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UVSP | GLUE |
|---|---|---|
| Price | $41.10 | $9.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $45.50 | $26.88 |
| AVG Volume (30 Days) | 194.2K | ★ 1.2M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $328,056,000.00 | $123,672,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | ★ $23.06 | $72.42 |
| Revenue Growth | 9.64 | ★ 63.54 |
| 52 Week Low | $28.04 | $8.94 |
| 52 Week High | $45.46 | $25.77 |
Technical Indicators
Market Signals| Indicator | UVSP | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 29.77 |
| Support Level | $40.49 | $9.68 |
| Resistance Level | $42.10 | $12.26 |
| Average True Range (ATR) | 0.70 | 0.56 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 60.14 | 8.14 |
Price Performance
Historical ComparisonAbout UVSP Univest Financial Corporation
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).